Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Cholecystokinin and the hormone concept

    Research output: Contribution to journalReviewpeer-review

  2. Determining minimal important change for the thyroid-related quality of life questionnaire ThyPRO

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Free testosterone and cardiometabolic parameters in men: comparison of algorithms

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The economic impact of prevention, monitoring and treatment strategies for iodine deficiency disorders in Germany

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Identification of a unique epigenetic profile in women with diminished ovarian reserve

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Anabolic-Androgenic Steroid Abuse Impairs Fibrin Clot Lysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of Anabolic-Androgenic Steroid Abuse on the Contact Activation System

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on some markers of VTE and CVD, in PCOS. In a double-blind, placebo-controlled, randomized trial 72 overweight and/or insulin resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference, from baseline to 26-week follow-up, in change in thrombin generation test parameters: Endogenous thrombin potential, peak thrombin concentration, lag-time and time-to-peak, and in levels of plasminogen activator inhibitor-1. Mean weight loss was 5.2 kg (95%CI 3.0-7.5 kg, p<0.001) in the liraglutide group compared with placebo. We detected no effect on endogenous thrombin potential in either group. In the liraglutide group peak thrombin concentration decreased by 16.71 nmol/L (95%CI 2.32-31.11, p<0.05) and lag-time and time-to-peak increased by 0.13 min (95%CI 0.01-0.25, p<0.05) and 0.38 min (95%CI 0.09-0.68, p<0.05), respectively, but there were no between-group differences. Plasminogen activator inhibitor-1 decreased by 12% (95%CI 0-23, p=0.05) with liraglutide and there was a trend towards 16% (95%CI -4-32, p=0.10) reduction, compared with placebo. In overweight women with PCOS, liraglutide intervention caused an approximate 5% weight loss. In addition, liraglutide affected thrombin generation, although not significantly differently from placebo. A concomitant trend towards improved fibrinolysis indicates a possible reduction of the baseline thrombogenic potential. The findings point towards beneficial effects of liraglutide on markers of VTE and CVD risk, which should be further pursued in larger studies.

Original languageEnglish
JournalEndocrine Connections
Volume6
Issue number2
Pages (from-to)89-99
Number of pages24
ISSN2049-3614
DOIs
Publication statusPublished - 24 Jan 2017

ID: 49809786